Aripiprazole – a collection of handful information for the practitioner Review article
Article Sidebar
Published:
Mar 31, 2021
Keywords:
aripiprazole, extrapyramidal effects, safety profile, the elderly, cardiac safety
Main Article Content
Abstract
Aripiprazole is an atypical neuroleptic used in schizophrenia and bipolar I disorder. It has low risk of inducing extrapyramidal symptoms and QT prolongation. It has favorable safety profile (including the metabolic one), so it can be used in somatically burdened patients, patients over 65 years of age, and obese patients. The drug in low doses has an activating and antidepressant effect, while in doses exceeding 20 mg/24 h – antipsychotic and anti-manic.
Article Details
How to Cite
Antosik-Wójcińska, A. (2021). Aripiprazole – a collection of handful information for the practitioner. Medycyna Faktow (J EBM), 14(1(50), 93-97. https://doi.org/10.24292/01.MF.0121.12
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Szulc A, Dudek D, Samochowiec J, Wojnar M et al. Rekomendacje dotyczące leczenia schizofrenii z objawami negatywnymi. Standardy farmakoterapii Polskiego Towarzystwa Psychiatrycznego, część 2. Psychiatr Pol. ONLINE FIRST 2019; 129: 1-16.
2. Schatzberg AF, Nemeroff CB (eds). The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed., American Psychiatric Publishing, Washington, D.C. 2009.
3. El-Sayeh HG, Morganti C, Adams CE: Aripiprazole for schizophrenia. Systematic review. Br J Psychiatry 2006; 189: 102-108.
4. Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763-771.
5. Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003; 60: 681-690.
6. Khanna P, Suo T, Komossa K et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014; 1: CD006569.
7. Dhillon S. Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder. Drugs 2012; 72: 133-162.
8. Li DJ, Tseng PT, Stubbs B et al. Efficacy, safety and tolerability of aripiprazole in bipolar disorder: an updated systematic review and meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 79: 289-301.
9. Fountoulakis KN, Grunze H, Vieta E et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017). Part 3: The Clinical Guidelines. Int J Neuropsychopharmacol. 2017; 20(2): 180-95.
10. Vieta E, Bourin M, Sanchez R et al.; Aripiprazole Study Group: Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005; 187: 235-242.
11. Young AH, Oren DA, Lowy A et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psych 2009; 194: 40-48.
12. Yatham LN. Clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder. Clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder. J Affective Disord. 2011; 12851: 21-28.
13. Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015; 11: 2635-2647.
14. Więdłocha M, Szulc A. Częściowy agonizm, pełna skuteczność – profil farmakologiczny i zastosowanie kliniczne arypiprazolu. Psychiatria 2017; 14(1): 1-6.
15. Wang LJ, Ree SC, Huang YS et al. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 40: 260-6.
16. Kim E, You M, Pikalov A et al. One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis. BMC Psychiatry 2011; 11: 6.
17. Meng M, Li W, Zhang S et al. Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Arch Psychiatry 2015; 27(1): 4-17.
18. Chen JX, Su YA, Bian QT et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology 2015; 58: 130-140.
19. Citrome L, Eramo A, Francois C et al. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatr Dis Treat. 2015; 11: 3095-3104.
20. Ostinelli EG, D’Agostino A, Shokraneh F et al. Acute interventions for aggression and agitation in psychosis: study protocol for a systematic review and network meta-analysis. BMJ Open 2019; 9(10): e032726.
2. Schatzberg AF, Nemeroff CB (eds). The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed., American Psychiatric Publishing, Washington, D.C. 2009.
3. El-Sayeh HG, Morganti C, Adams CE: Aripiprazole for schizophrenia. Systematic review. Br J Psychiatry 2006; 189: 102-108.
4. Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763-771.
5. Potkin SG, Saha AR, Kujawa MJ et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003; 60: 681-690.
6. Khanna P, Suo T, Komossa K et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014; 1: CD006569.
7. Dhillon S. Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder. Drugs 2012; 72: 133-162.
8. Li DJ, Tseng PT, Stubbs B et al. Efficacy, safety and tolerability of aripiprazole in bipolar disorder: an updated systematic review and meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 79: 289-301.
9. Fountoulakis KN, Grunze H, Vieta E et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017). Part 3: The Clinical Guidelines. Int J Neuropsychopharmacol. 2017; 20(2): 180-95.
10. Vieta E, Bourin M, Sanchez R et al.; Aripiprazole Study Group: Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005; 187: 235-242.
11. Young AH, Oren DA, Lowy A et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psych 2009; 194: 40-48.
12. Yatham LN. Clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder. Clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder. J Affective Disord. 2011; 12851: 21-28.
13. Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015; 11: 2635-2647.
14. Więdłocha M, Szulc A. Częściowy agonizm, pełna skuteczność – profil farmakologiczny i zastosowanie kliniczne arypiprazolu. Psychiatria 2017; 14(1): 1-6.
15. Wang LJ, Ree SC, Huang YS et al. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 40: 260-6.
16. Kim E, You M, Pikalov A et al. One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis. BMC Psychiatry 2011; 11: 6.
17. Meng M, Li W, Zhang S et al. Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Arch Psychiatry 2015; 27(1): 4-17.
18. Chen JX, Su YA, Bian QT et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology 2015; 58: 130-140.
19. Citrome L, Eramo A, Francois C et al. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatr Dis Treat. 2015; 11: 3095-3104.
20. Ostinelli EG, D’Agostino A, Shokraneh F et al. Acute interventions for aggression and agitation in psychosis: study protocol for a systematic review and network meta-analysis. BMJ Open 2019; 9(10): e032726.